Spotlight on JLABS

Apr 18 2017

Interested in starting a company, investing, or just curious about the current state of innovation in San Diego? Then YOU are invited to JLABS on April 18th to meet, greet, and see short presentations on some of our standout companies. Space is limited, so don't miss out!

Did you know that JLABS San Diego is home to nearly 50 emerging companies? On April 18th, JLABS will shine the spotlight on three of our resident companies: Actavalon, Gene Sciences and ProdermIQ. Join us to see how they're moving innovation forward, right here in San Diego.

Please note that the presentations at this event will include publicly available, non-confidential information only.

Tuesday, April 18, 2017

11:30am | Lunch
12:00pm | Presentations
1:00pm | Program Close

Presenting Companies:
Actavalon read more»
Gene Sciences read more»
ProdermIQ read more»

Please RSVP online so that we can get an accurate headcount for food and beverages. We will not be accepting walk-ups once the event is sold out.

3210 Merryfield Row
San Diego, CA

Presenting Companies' Descriptions:

Actavalon is a preclinical stage oncology drug company targeting two fundamental cancer pathways, neither of which is adequately addressed by current therapies – the p53 tumor suppressor and the PI3K/AKT pathways. In order for cancer cells to survive and multiply, the innate human p53 tumor suppressor mechanism must be inactivated. In over half of all tumors such inactivation results from a mutation in the p53 gene. Actavalon scientists have discovered and developed novel small molecules capable of restoring the p53 tumor suppression mechanism in p53 cancer cell mutants, leading to rapid cancer cell death regardless of tissue origin. Although kinase inhibitors of the PI3K/AKT pathway have been developed as cancer therapeutics, their efficacies are generally limited by off-target effects. Actavalon scientists have developed small molecule, non-kinase, modulators of this pathway with nanomolar potency and selectivity for relevant cancers with favorable pharmokinetic properties and very low toxicity in other cells. Since these compounds have a non-kinase target they may represent a novel drug class for precision cancer therapy.

Gene Sciences Gene Sciences, Inc is developing therapeutics that modulate gene expression at the protein-DNA interface for the treatment of human diseases. Based on technology stemming from the research of the Dervan laboratory at the California Institute of Technology, we are advancing polyamides as first-in-class therapeutics that disrupt signaling of oncogenic transcription factors. Our preclinical candidate, GSI-609, has demonstrated efficacy in prostate cancer models and has a clean preliminary toxicity profile. The Gene Sciences team has extensive experience in cancer drug development and is located in La Jolla, CA.

ProdermIQ, Inc. is a skin health startup utilizing the power of lifestyle, demographic and clinical data integrated with our industry leading proprietary microbiome analysis platform to create a deeper understanding of skin and skin health and enabling novel drug discovery and product development. ProdermIQ’s advanced approach to skin health delivers valuable data, actionable insights and novel interventions to our corporate clients ultimately delivering value to the professional and consumer markets. By integrating our testing, real-time data acquisition, and machine learning analytics platform we provide individual skin profiles, skin biomarkers and novel therapeutic targets to some of the world’s largest skin care companies and academic institutions.